4-(1-methylpiperidin-4-ylamino)-3-nitrobenzenesulfonamide | 1228780-76-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(1-methylpiperidin-4-ylamino)-3-nitrobenzenesulfonamide
• 英文别名: 4-[(1-Methylpiperidin-4-yl)amino]-3-nitrobenzenesulfonamide
• CAS: 1228780-76-4
• 化学式: C₁₂H₁₈N₄O₄S
• 分子量: 314.365
• InChiKey: HGBNUFIOPVXIKI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  130
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-(1-methylpiperidin-4-ylamino)-3-nitrobenzenesulfonamide 、 4-((4aS,10aR)-14-(4-chlorophenyl)-12,12-dimethyl-1,2,4a,5,8,9,10a,11,12,13-decahydrobenzo[f]pyrazino[2,1-c][1,8,4]dioxaazacycloundecin-3(4H,7H,15H)-yl)-2-(2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepin-1-yl)benzoic acid 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 4-((4aS,10aR)-14-(4-chlorophenyl)-12,12-dimethyl-1,2,4a,5,8,9,10a,11,13,15-decahydro-7H,12H-benzo[f]pyrazino[2,1-c][1,8]dioxa[4]azacycloundecin-3(4H)-yl)-2-(3,4-dihydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)-yl)-N-((4-((1-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide
  参考文献：
  名称：

  [EN] 1,3,4,7-TETRAHYDRO-2H-PYRROLO [3',2':5,6] PYRIDO[2,3-B] [1,4] OXAZEPINE BC1-2 INHIBITORS
  [FR] INHIBITEURS DE BCL-2 DE TYPE 1,3,4,7-TÉTRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZÉPINE

  摘要：

  The present invention provides for compounds of Formula (I) wherein A, L, W, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL, SLL, and/or ALL.

  公开号：

  WO2023141536A1
• 作为产物：
  描述：

  4-氨基-1-甲基哌啶 、 3-硝基-4-氯苯磺酰胺 以 1,4-二氧六环 为溶剂， 生成 4-(1-methylpiperidin-4-ylamino)-3-nitrobenzenesulfonamide
  参考文献：
  名称：

  [EN] 1,3,4,7-TETRAHYDRO-2H-PYRROLO [3',2':5,6] PYRIDO[2,3-B] [1,4] OXAZEPINE BC1-2 INHIBITORS
  [FR] INHIBITEURS DE BCL-2 DE TYPE 1,3,4,7-TÉTRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZÉPINE

  摘要：

  The present invention provides for compounds of Formula (I) wherein A, L, W, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL, SLL, and/or ALL.

  公开号：

  WO2023141536A1

文献信息

• APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
  申请人：Bruncko Milan

  公开号：US20100305122A1

  公开（公告）日：2010-12-02

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

  揭示了抑制抗凋亡Bcl-2蛋白活性的化合物，含有这些化合物的组合物以及治疗在其中表达抗凋亡Bcl-2蛋白的疾病的方法。
• APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
  申请人：Bruncko Milan

  公开号：US20100160322A1

  公开（公告）日：2010-06-24

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

  揭示了抑制抗凋亡Bcl-2蛋白活性的化合物，含有这些化合物的组合物以及治疗在其中表达抗凋亡Bcl-2蛋白的疾病的方法。
• MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
  申请人：Birtalan Esther

  公开号：US20120108590A1

  公开（公告）日：2012-05-03

  A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of Formula I, the water-soluble polymeric carrier and the surfactant, to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; and cooling the resulting extrudate to to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer or an immune or autoimmune disease.

  一种促凋亡的固态分散物包括本文所定义的化合物I公式的Bcl-2家族蛋白抑制剂，以基本非结晶形式分散在固态基质中，该基质包括（a）药学上可接受的水溶性聚合物载体和（b）药学上可接受的表面活性剂。制备这种固态分散物的过程包括将公式I的化合物、水溶性聚合物载体和表面活性剂暴露于高温下，以提供可挤出的半固体混合物；挤出半固体混合物；并冷却所得到的挤出物，以提供包含聚合物载体和表面活性剂的固态基质，并在其中分散化合物的基本非结晶形式。这种固态分散物适用于口服给予需要治疗由一个或多个抗凋亡Bcl-2家族蛋白过度表达所特征的疾病的患者，例如癌症或免疫或自身免疫性疾病。
• [EN] SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT<br/>[FR] DISPERSIONS SOLIDES CONTENANT UN AGENT INDUISANT L'APOPTOSE
  申请人：ABBOTT LAB

  公开号：WO2012058392A1

  公开（公告）日：2012-05-03

  A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

  一种促凋亡的固体分散体包括本文所定义的化合物I的Bcl-2家族蛋白抑制剂，在基本非晶态形式下分散在固体基质中，该固体基质包括（a）一种药用可接受的水溶性聚合物载体和（b）一种药用可接受的表面活性剂。制备这种固体分散体的过程包括在适当的溶剂中溶解化合物、聚合物载体和表面活性剂，并去除溶剂，以提供包含聚合物载体和表面活性剂的固体基质，并在其中分散化合物的基本非晶态形式。该固体分散体适用于口服给予需要治疗一种或多种抗凋亡Bcl-2家族蛋白过度表达的疾病的受试者，例如癌症。
• SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
  申请人：Catron Nathaniel

  公开号：US20120277210A1

  公开（公告）日：2012-11-01

  A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

  一种促凋亡的固体分散物，其主要以非晶态形式分散在固体基质中，该基质包括以下成分：(a)一种药用可接受的水溶性聚合物载体和(b)一种药用可接受的表面活性剂，其中所述化合物为以下公式I所定义的Bcl-2家族蛋白抑制剂。制备这种固体分散物的方法包括将化合物、聚合物载体和表面活性剂溶解在适宜的溶剂中，并去除溶剂以提供包含聚合物载体和表面活性剂并在其中以基本非晶态形式分散有化合物的固体基质。该固体分散物适用于口服给予需要治疗由一个或多个抗凋亡Bcl-2家族蛋白过度表达引起的疾病，例如癌症的患者。